Table 2.
Description of heart rate variability (HRV) parameters (nHF, nLF, LF/HF, mean HR and mean RR) after diluent inhalation compared to inhalation of endogenous TRPV1 modulators (PGE2 and BK).
| Diluent | Prostaglandin-E2 | p* | |
|---|---|---|---|
| HF (n.u.) | 28.7 (23.2–42.7) | 14.1 (11.3–22.6) | 0.0022 |
| LF (n.u.) | 71.2 (57.3–76.8) | 85.9 (77.4–89.0) | 0.0022 |
| LF/HF | 2.5 (1.4–3.3) | 6.1 (3.6–7.9) | 0.0022 |
| Mean HR | 64 (58–71) | 86 (81–90) | 0.0022 |
| Mean RR (ms) | 964 (844–1,039) | 707 (660–772) | 0.0022 |
| Diluent | Bradykinin | p* | |
|---|---|---|---|
| HF (n.u.) | 24.8 (17.1–42.5) | 19.2 (11.6–23.6) | 0.0166 |
| LF (n.u.) | 75.1 (57.5–82.9) | 80.7 (76.4–88.4) | 0.0166 |
| LF/HF | 3.28 (1.35–4.9) | 4.2 (3.2–7.6) | 0.0218 |
| Mean HR | 67 (62–79) | 68 (66–84) | 0.066 |
| Mean RR (ms) | 897 (755–968) | 878 (713–907) | 0.046 |
Value are expressed as median (IQR25–75). * Wilcoxon Signed Rank Test.